2. Search Result
Search Result
Results for "

Pilocarpine

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0726
    Pilocarpine Hydrochloride
    40+ Cited Publications

    		 mAChR Cardiovascular Disease Neurological Disease Cancer
    Pilocarpine Hydrochloride is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine Hydrochloride
  • HY-B0726A
    Pilocarpine
    Maximum Cited Publications
    41 Publications Verification

    		 mAChR Neurological Disease Cancer
    Pilocarpine is a selective M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine
  • HY-B1006
    Pilocarpine nitrate
    40+ Cited Publications

    		 mAChR Neurological Disease Cancer
    Pilocarpine nitrate is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine nitrate
  • HY-164049
    TG8-260

    		Prostaglandin Receptor Inflammation/Immunology
    TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
    TG8-260
  • HY-103232
    IEM-1925 bromide

    		mGluR Neurological Disease
    IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .
    IEM-1925 bromide
  • HY-100265
    Cinperene

    R5046

    		 Drug Derivative Neurological Disease
    Cinperene is an atropine-like agent which can block pilocarpine-induced lacrimation and salivation.
    Cinperene
  • HY-B0726R
    Pilocarpine Hydrochloride (Standard)

    		Reference Standards mAChR Neurological Disease Cancer
    Pilocarpine (Hydrochloride) (Standard) is the analytical standard of Pilocarpine (Hydrochloride). This product is intended for research and analytical applications. Pilocarpine Hydrochloride is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine Hydrochloride (Standard)
  • HY-B0726S
    Pilocarpine-d3 hydrochloride

    		Isotope-Labeled Compounds mAChR Neurological Disease
    Pilocarpine-d3 (hydrochloride) is deuterium labeled Pilocarpine (Hydrochloride). Pilocarpine Hydrochloride is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine-d3 hydrochloride
  • HY-B0726S1
    Pilocarpine-d5 hydrochloride

    		mAChR Isotope-Labeled Compounds Neurological Disease Cancer
    Pilocarpine-d5 hydrochloride is deuterated labeled Pilocarpine hydrochloride (HY-B0726). Pilocarpine Hydrochloride is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine-d5 hydrochloride
  • HY-B1006R
    Pilocarpine nitrate (Standard)

    		Reference Standards mAChR Neurological Disease Cancer
    Pilocarpine (nitrate) (Standard) is the analytical standard of Pilocarpine (nitrate). This product is intended for research and analytical applications. Pilocarpine nitrate is a potent M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
    Pilocarpine nitrate (Standard)
  • HY-178362
    CAII/VII-IN-1

    		Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .
    CAII/VII-IN-1
  • HY-149422
    NIR-FP

    		Fluorescent Dye Neurological Disease
    NIR-FP is a near-infrared fluorescent probe with high sensitivity and selectivity for superoxide anion O 2-. O 2- is the main precursor of ROS, and ferroptosis-mediated epilepsy models can be dynamically tracked by detecting O 2-. Ferroptosis-mediated epilepsy models include: kainic acid (HY-N2309)-induced chronic epilepsy model, Pentylenetetrazole-induced acute epilepsy model, and pilocarpine (HY-B0726A)-induced epilepsy model .
    NIR-FP
  • HY-179142
    COX-2-IN-60

    		COX TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC50 of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC50 = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .
    COX-2-IN-60
  • HY-135754
    Tiquizium bromide

    HSR-902

    		 mAChR Neurological Disease Inflammation/Immunology
    Tiquizium bromide is an orally active, atropine-type, nonselective muscarinic antagonist and novel spasmolytic agent. Tiquizium bromide inhibits the developments of gastric lesions and duodenal lesions. Tiquizium bromide induces the mydoriasis and inhibits the Pilocarpine (HY-B0726A)-induced salivation .
    Tiquizium bromide
  • HY-180056
    CAII-IN-12

    		Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
    CAII-IN-12
  • HY-183149
    BPN-37440

    		Prostaglandin Receptor Interleukin Related COX Neurological Disease
    BPN-37440 is a blood-brain barrier-permeable, selective, and orally active EP2 receptor inhibitor with an IC50 of 53-60 nM. BPN-37440 inhibits the expression of inflammatory mediators IL-1β and COX-2, with an IC50 of 21 nM for IL-1β and 42 nM for COX-2. BPN-37440 reduces microgliosis in key brain regions of mice with pilocarpine (HY-B0726A)-induced status epilepticus and reverses their working memory and recognition memory deficits. BPN-37440 can be used for research on status epilepticus .
    BPN-37440
  • HY-114833
    Bunolol

    (Rac)-Bunolol; dl-Bunolol

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Bunolol ((Rac)-Bunolol) is a β-adrenergic receptor blocker. Bunolol antagonizes the β-receptor agonist activity induced by Isoproterenol (HY-B0468) and Dichloroisoproterenol. Bunolol reduces the heart rate and mean blood pressure of anesthetized dogs. Bunolol decreases spontaneous motor activity and Amphetamine-induced hyperactivity in rats, potentiates Pentobarbital-induced hypnosis in mice, and protects rats from extensor tonic convulsions induced by maximal electroshock .
    Bunolol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: